These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 2760566)

  • 41. Prenatal diagnosis of chondrodysplasia punctata by sonography.
    Duff P; Harlass FE; Milligan DA
    Obstet Gynecol; 1990 Sep; 76(3 Pt 2):497-500. PubMed ID: 2199870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Peroxisomal disorders; newer concept and recent studies].
    Kamoshita S
    Nihon Rinsho; 1990 Mar; 48(3):629-38. PubMed ID: 2192101
    [No Abstract]   [Full Text] [Related]  

  • 43. Incidence of peroxisomal disorders in Japan.
    Suzuki Y; Shimozawa N; Yajima S; Inoue K; Orii T; Kondo N
    Jpn J Hum Genet; 1996 Mar; 41(1):167-75. PubMed ID: 8914632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Chondrodysplasia punctata (the Conradi-Hünermann syndrome). A clinical case report and review of the literature].
    Omobono E; Goetsch W
    Minerva Pediatr; 1993 Mar; 45(3):117-21. PubMed ID: 8341225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peroxisomal disorders. Neurodevelopmental and biochemical aspects.
    Brown FR; Voigt R; Singh AK; Singh I
    Am J Dis Child; 1993 Jun; 147(6):617-26. PubMed ID: 7685145
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inherited disorders of fatty alcohol metabolism.
    Rizzo WB
    Mol Genet Metab; 1998 Oct; 65(2):63-73. PubMed ID: 9787098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Zellweger syndrome and other peroxisomal disorders: I. Clinical characteristics of a recently discovered group of diseases].
    Heymans HS; Wanders RJ; Schutgens RB; van den Bosch H; Tager JM; Barth PG
    Ned Tijdschr Geneeskd; 1990 Mar; 134(13):634-9. PubMed ID: 1690863
    [No Abstract]   [Full Text] [Related]  

  • 48. Essential fatty acids and serine as plasmalogen precursors in relation to competing metabolic pathways.
    Cook HW; Thomas SE; Xu Z
    Biochem Cell Biol; 1991 Jul; 69(7):475-84. PubMed ID: 1793558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age-related differences in plasmalogen content of erythrocytes from patients with the cerebro-hepato-renal (Zellweger) syndrome: implications for postnatal detection of the disease.
    Wanders RJ; Purvis YR; Heymans HS; Bakkeren JA; Parmentier GG; van Eldere J; Eyssen H; van den Bosch H; Tager JM; Schutgens RB
    J Inherit Metab Dis; 1986; 9(4):335-42. PubMed ID: 3104670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor.
    Wood PL; Khan MA; Smith T; Ehrmantraut G; Jin W; Cui W; Braverman NE; Goodenowe DB
    Lipids Health Dis; 2011 Oct; 10():182. PubMed ID: 22008564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolism of branched chain fatty acids in peroxisomal disorders.
    Singh H; Usher S; Johnson D; Poulos A
    J Inherit Metab Dis; 1990; 13(3):387-9. PubMed ID: 1700192
    [No Abstract]   [Full Text] [Related]  

  • 52. Peroxisomal diseases.
    Goldfischer SL
    Prog Clin Biol Res; 1988; 282():117-37. PubMed ID: 3071793
    [No Abstract]   [Full Text] [Related]  

  • 53. History of the cerebrohepatorenal syndrome of Zellweger and other peroxisomal disorders.
    Zellweger H; Maertens P; Superneau D; Wertelecki W
    South Med J; 1988 Mar; 81(3):357-64. PubMed ID: 2450404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ether lipid synthesis and its deficiency in peroxisomal disorders.
    van den Bosch H; Schrakamp G; Hardeman D; Zomer AW; Wanders RJ; Schutgens RB
    Biochimie; 1993; 75(3-4):183-9. PubMed ID: 8507680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Studies on the degradation of [U-3H]-phytanic acid and [U-3H]-pristanic acid in cultured fibroblasts from children with peroxisomal disorders.
    Kase BF; Björkhem I
    Scand J Clin Lab Invest; 1996 May; 56(3):211-7. PubMed ID: 8761525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes.
    Kelley RI; Datta NS; Dobyns WB; Hajra AK; Moser AB; Noetzel MJ; Zackai EH; Moser HW
    Am J Med Genet; 1986 Apr; 23(4):869-901. PubMed ID: 3515938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical biochemistry of peroxisomal disorders.
    Kaiser E; Kramar R
    Clin Chim Acta; 1988 Mar; 173(1):57-80. PubMed ID: 3289796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnosis of peroxisomal disorders by analysis of phytanic and pristanic acids in stored blood spots collected at neonatal screening.
    ten Brink HJ; van den Heuvel CM; Christensen E; Largillière C; Jakobs C
    Clin Chem; 1993 Sep; 39(9):1904-6. PubMed ID: 8375069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of plasma very long-chain fatty acids as a preliminary screening procedure for the diagnosis of peroxisomal disorders.
    Steinberg SJ; Fensom AH; Dalton NR; Toseland PA; Kennedy CR; Mowat AP
    J Inherit Metab Dis; 1994; 17(3):323-6. PubMed ID: 7807943
    [No Abstract]   [Full Text] [Related]  

  • 60. Clofibrate and other peroxisomal proliferating agents relatively specifically inhibit synthesis of ethanolamine phosphoglycerides in cultured human fibroblasts.
    Thorne PC; Byers DM; Palmer FB; Cook HW
    Biochim Biophys Acta; 1994 Sep; 1214(2):161-70. PubMed ID: 7918596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.